Pyxis Oncology (PYXS) Gross Profit (2024 - 2025)

Pyxis Oncology (PYXS) reported Gross Profit of $8.6 million for Q4 2025, up 206.74% quarter-over-quarter from $2.8 million in Q2 2025.

Pyxis Oncology (PYXS) Gross Profit (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has 2 years of Gross Profit data on file, last reported at $8.6 million in Q4 2025.

Gross Profit for Q4 2025 came in at $8.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $11.5 million (down 26.81% YoY), and the FY2025 annual result was $11.5 million, down 26.81% from the prior year.
Gross Profit rose to $8.6 million in Q4 2025 per PYXS's latest filing, from $2.8 million in the prior quarter.
Over five years, Gross Profit peaked at $15.7 million in Q1 2024 and troughed at $2.8 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Pyxis Oncology	125.84 Mn	108.95 Mn	8.65 Mn

Download Data